ALNY Alnylam Pharmaceuticals, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Below the channel · 3-year channel rising
Closed below support (US$218.48). Treat the buy level with caution.
- 3-year channel
- US$218.48 – US$245.95 · rising, +26% a year
- Price in channel
- −195% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$245.95
- Published levels
- Buy and target are not from this channel — see below.
What broke this trend
- The fall
- -66% from US$491.3420 Oct 2025 → 30 Oct 2026
- Whose problem it was
- This company0 of 7 Biotechnology peers fell with it
- Does it resolve?
- Permanent the record is against a recovery from here
- Regained so far
- 0%of what it lost
- What the record says
- 29% of 5 comparable falls came back, typically in 60 days measured on its own peer group
Fell -66% (20 Oct 2025 → 30 Oct 2026); regained 0% so far; company-specific.
Reported at the time: Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $535 — 17 Oct 2025
Price history, with the path projected 3 months forward
Updated 4:00 PM ET (44 h ago)
- Daily close
- Upper trend line (3 years)
- Lower trend line (3 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$164.90
level as at 1 Nov 2026
Our target
US$174.79
by 23 Nov 2026
Projected move
6.0%
gross, before costs
Price is at or below our buy.
Target: ALNY's usual move size (6.0%), the best return per day on this path.
This move size: reached in 81% of 8 past stretches, typically in 22 days. (0.27% per day)
- Upper line touches
- 5
- Lower line touches
- 4
- Fit confidence
- 33%
- Fitted
- 1 Nov 2026
Company information
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$35.65B
- Enterprise value
- —
- Beta
- 0.28
- Avg volume
- 1.58M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 197.81-495.55
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.